Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bias | 3 | 2022 | 42 | 1.040 |
Why?
|
| Reproducibility of Results | 4 | 2020 | 773 | 0.800 |
Why?
|
| Lymphoma | 1 | 2020 | 26 | 0.690 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 58 | 0.570 |
Why?
|
| Electrophoresis, Capillary | 2 | 2009 | 13 | 0.530 |
Why?
|
| Glutathione | 2 | 2009 | 72 | 0.520 |
Why?
|
| Circadian Rhythm | 2 | 2005 | 76 | 0.470 |
Why?
|
| Intelligence | 1 | 2014 | 27 | 0.450 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 534 | 0.440 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 62 | 0.430 |
Why?
|
| Copper | 2 | 2009 | 47 | 0.360 |
Why?
|
| Monte Carlo Method | 4 | 2022 | 62 | 0.340 |
Why?
|
| Liver Cirrhosis | 2 | 2011 | 72 | 0.330 |
Why?
|
| Plant Shoots | 1 | 2009 | 5 | 0.320 |
Why?
|
| Glutathione Disulfide | 1 | 2009 | 14 | 0.310 |
Why?
|
| Plant Roots | 1 | 2009 | 50 | 0.300 |
Why?
|
| Food Deprivation | 2 | 2005 | 11 | 0.300 |
Why?
|
| Eating | 2 | 2005 | 70 | 0.300 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 25 | 0.280 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 37 | 0.280 |
Why?
|
| Sorghum | 1 | 2006 | 1 | 0.260 |
Why?
|
| Psychometrics | 2 | 2012 | 121 | 0.260 |
Why?
|
| Sewage | 1 | 2006 | 21 | 0.260 |
Why?
|
| Metals | 1 | 2006 | 41 | 0.260 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2005 | 3 | 0.250 |
Why?
|
| Food Preferences | 1 | 2005 | 20 | 0.250 |
Why?
|
| Soil | 1 | 2006 | 87 | 0.240 |
Why?
|
| Sample Size | 2 | 2022 | 17 | 0.240 |
Why?
|
| Nucleus Accumbens | 1 | 2005 | 7 | 0.240 |
Why?
|
| Mustard Plant | 1 | 2004 | 2 | 0.220 |
Why?
|
| Metals, Heavy | 1 | 2004 | 14 | 0.220 |
Why?
|
| Feeding Behavior | 1 | 2005 | 102 | 0.220 |
Why?
|
| Computer Simulation | 2 | 2022 | 230 | 0.210 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2016 | 44 | 0.210 |
Why?
|
| Liver | 1 | 2006 | 434 | 0.200 |
Why?
|
| Immunosuppressive Agents | 2 | 2016 | 148 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-fos | 3 | 2005 | 14 | 0.180 |
Why?
|
| Geologic Sediments | 1 | 2021 | 68 | 0.180 |
Why?
|
| Confidence Intervals | 1 | 2000 | 68 | 0.170 |
Why?
|
| Biodiversity | 1 | 2021 | 112 | 0.170 |
Why?
|
| Models, Psychological | 2 | 2012 | 81 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2018 | 554 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 300 | 0.160 |
Why?
|
| Infliximab | 2 | 2016 | 10 | 0.150 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2018 | 12 | 0.150 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2018 | 8 | 0.150 |
Why?
|
| Mucin-2 | 1 | 2018 | 6 | 0.150 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 521 | 0.150 |
Why?
|
| Humans | 13 | 2020 | 28121 | 0.140 |
Why?
|
| Cell Count | 3 | 2005 | 86 | 0.130 |
Why?
|
| Likelihood Functions | 1 | 2016 | 27 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 677 | 0.130 |
Why?
|
| Rats, Wistar | 3 | 2005 | 151 | 0.130 |
Why?
|
| Gastritis, Atrophic | 1 | 2016 | 2 | 0.130 |
Why?
|
| Adalimumab | 1 | 2016 | 4 | 0.130 |
Why?
|
| Stomach | 1 | 2016 | 43 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2016 | 17 | 0.130 |
Why?
|
| Time Factors | 4 | 2016 | 1593 | 0.120 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 462 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2016 | 25 | 0.120 |
Why?
|
| Crohn Disease | 2 | 2013 | 32 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 120 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2016 | 94 | 0.120 |
Why?
|
| Motor Activity | 2 | 2005 | 147 | 0.110 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2013 | 5 | 0.110 |
Why?
|
| Rats | 3 | 2005 | 1564 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 297 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 77 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 166 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 329 | 0.090 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2011 | 4 | 0.090 |
Why?
|
| Methotrexate | 1 | 2011 | 34 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 25 | 0.090 |
Why?
|
| Male | 8 | 2016 | 13487 | 0.090 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1014 | 0.080 |
Why?
|
| Spain | 3 | 2016 | 17 | 0.080 |
Why?
|
| Reference Standards | 1 | 2009 | 57 | 0.080 |
Why?
|
| Genotype | 3 | 2018 | 457 | 0.080 |
Why?
|
| Psychology | 1 | 2007 | 19 | 0.070 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 40 | 0.070 |
Why?
|
| Middle Aged | 5 | 2018 | 7164 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2011 | 1249 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 4 | 0.060 |
Why?
|
| Transducers | 1 | 2006 | 7 | 0.060 |
Why?
|
| Adult | 5 | 2018 | 7757 | 0.060 |
Why?
|
| Hepatitis B | 1 | 2006 | 13 | 0.060 |
Why?
|
| Biomass | 1 | 2006 | 86 | 0.060 |
Why?
|
| Midline Thalamic Nuclei | 1 | 2005 | 1 | 0.060 |
Why?
|
| Geniculate Bodies | 1 | 2005 | 3 | 0.060 |
Why?
|
| Period Circadian Proteins | 1 | 2005 | 2 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 48 | 0.060 |
Why?
|
| Darkness | 1 | 2005 | 17 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2018 | 413 | 0.060 |
Why?
|
| Elasticity | 1 | 2006 | 52 | 0.060 |
Why?
|
| Arousal | 1 | 2005 | 38 | 0.060 |
Why?
|
| Sampling Studies | 2 | 2007 | 24 | 0.060 |
Why?
|
| Hepatitis C, Chronic | 1 | 2006 | 32 | 0.060 |
Why?
|
| Forecasting | 1 | 2006 | 75 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2006 | 52 | 0.060 |
Why?
|
| Reward | 1 | 2005 | 45 | 0.060 |
Why?
|
| Disease Progression | 2 | 2018 | 473 | 0.060 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2005 | 5 | 0.060 |
Why?
|
| N-Methylaspartate | 1 | 2005 | 4 | 0.060 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2005 | 22 | 0.060 |
Why?
|
| Liver Transplantation | 1 | 2006 | 56 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2006 | 241 | 0.060 |
Why?
|
| Random Allocation | 1 | 2005 | 151 | 0.060 |
Why?
|
| Brain Stem | 1 | 2004 | 23 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 372 | 0.060 |
Why?
|
| Food | 1 | 2004 | 33 | 0.060 |
Why?
|
| Behavior, Animal | 1 | 2005 | 107 | 0.060 |
Why?
|
| Mercaptoethanol | 1 | 2004 | 5 | 0.060 |
Why?
|
| Electrolytes | 1 | 2004 | 11 | 0.060 |
Why?
|
| Cadmium | 1 | 2004 | 16 | 0.060 |
Why?
|
| Body Weight | 1 | 2005 | 250 | 0.050 |
Why?
|
| Eye Proteins | 1 | 2005 | 205 | 0.050 |
Why?
|
| HIV Infections | 1 | 2006 | 157 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2004 | 267 | 0.050 |
Why?
|
| Animals | 3 | 2005 | 10399 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 362 | 0.050 |
Why?
|
| Chile | 1 | 2021 | 9 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 18 | 0.050 |
Why?
|
| Gene Frequency | 2 | 2013 | 185 | 0.040 |
Why?
|
| Haplotypes | 2 | 2013 | 283 | 0.040 |
Why?
|
| Alleles | 2 | 2013 | 353 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 324 | 0.040 |
Why?
|
| Female | 5 | 2016 | 15156 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2021 | 306 | 0.040 |
Why?
|
| Phylogeny | 1 | 2021 | 480 | 0.040 |
Why?
|
| Helicobacter pylori | 1 | 2018 | 18 | 0.040 |
Why?
|
| Helicobacter Infections | 1 | 2018 | 17 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2016 | 2380 | 0.040 |
Why?
|
| Metaplasia | 1 | 2016 | 5 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 113 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2016 | 1 | 0.030 |
Why?
|
| Universities | 1 | 2016 | 120 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 13 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 248 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 226 | 0.030 |
Why?
|
| Biopsy | 1 | 2016 | 207 | 0.030 |
Why?
|
| Aged | 2 | 2018 | 5416 | 0.030 |
Why?
|
| Students | 1 | 2016 | 196 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 242 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 611 | 0.030 |
Why?
|
| Algorithms | 1 | 2016 | 433 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 237 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 969 | 0.020 |
Why?
|
| Psoriasis | 1 | 2011 | 7 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 45 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 223 | 0.020 |
Why?
|
| Risk Factors | 1 | 2016 | 2084 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 407 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 134 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 605 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2016 | 2557 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 56 | 0.020 |
Why?
|
| Heterozygote | 1 | 2007 | 65 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 146 | 0.020 |
Why?
|
| Colitis, Ulcerative | 1 | 2007 | 31 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 584 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 2021 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 2731 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2007 | 722 | 0.020 |
Why?
|
| Postprandial Period | 1 | 2004 | 44 | 0.010 |
Why?
|
| Fasting | 1 | 2004 | 81 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 282 | 0.010 |
Why?
|